Medacta Group SA (XSWX:MOVE)

CHF 110.2 3.6 (3.38%) Market Cap: 2.20 Bil Enterprise Value: 2.22 Bil PE Ratio: 41.03 PB Ratio: 6.64 GF Score: 93/100

Full Year 2023 Medacta Group SA Earnings Call Transcript
Mar 13, 2024

CHF125.4 (-0.48%)

Earnings
Full Year 2023 Medacta Group SA Corporate Sales Call Transcript
Feb 02, 2024
Half Year 2023 Medacta Group SA Earnings Call Transcript
Sep 22, 2023

CHF121.2 (-1.78%)

Earnings
Half Year 2023 Medacta Group SA Corporate Sales Call Transcript
Jul 28, 2023
Full Year 2022 Medacta Group SA Earnings Call Transcript
Mar 17, 2023

CHF104 (+0.39%)

Earnings
Q4 2022 Medacta Group SA Unaudited Top-Line Figures Call Transcript
Feb 03, 2023
Half Year 2022 Medacta Group SA Earnings Call Transcript
Sep 09, 2022

CHF88.7 (+2.31%)

Earnings
Half Year 2022 Medacta Group SA Earnings Call Transcript
Jul 29, 2022

CHF94.1 (+1.84%)

Earnings
Full Year 2021 Medacta Group SA Earnings Call Transcript
Mar 11, 2022

CHF110.2 (-4.67%)

Earnings
Q4 2021 Medacta Group SA Corporate Sales Call Transcript
Jan 20, 2022
Half Year 2021 Medacta Group SA Earnings Call Transcript
Sep 10, 2021

CHF146.8 (+3.53%)

Earnings
Half Year 2021 Medacta Group SA Corporate Sales Call Transcript
Jul 20, 2021
Full Year 2020 Medacta Group SA Earnings Call Transcript
Mar 31, 2021

CHF101.6 (-6.62%)

Earnings
Full Year 2020 Medacta Group SA Corporate Sales Call Transcript
Jan 21, 2021
Half Year 2020 Medacta Group SA Earnings Call Transcript
Sep 07, 2020

CHF87 (+3.94%)

Earnings
Half Year 2020 Medacta Group SA Earnings Call Transcript
Jul 22, 2020

CHF87 (+2.47%)

Earnings
Full Year 2019 Medacta Group SA Earnings Call Transcript
Apr 06, 2020

Earnings

Half Year 2020 Medacta Group SA Earnings Call Transcript

Jul 22, 2020 / 01:00PM GMT

Release Date Price: CHF87 (+2.47%)

Transcript

Operator

Dear ladies and gentlemen, welcome to the conference call of Medacta Group SA. At our customer's request, this conference will be recorded. (Operator Instructions)

May I now hand you over to Medacta CEO, Mr. Francesco Siccardi, who will lead you through this conference. Please go ahead, sir.

Francesco Siccardi

Medacta Group SA - Founder, CEO & Member of the Group Executive Management

Good afternoon, ladies and gentlemen, and thank you for joining Medacta's H1 unaudited top line figures. I will be presenting most of the slides today. And for the Q&A, I will be, together with Corrado Farsetta, able to answer any question you might have.

So if we go through the slides, we can, I think, jump after the disclosures, Corrado, on Slide #4. We have been, of course, affected during the H1 by the COVID situation. As we all know, this has caused elective surgeries to be deferred in many countries. The impact of these orthopedic surgeries deferral has been very different from country to country. And this clearly reflects on the differences across

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.